<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
		<previousAccessionNumber>0001415889-25-001009</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002050755</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
	      <securitiesClassTitle>Common Stock, par value $.0001 per share</securitiesClassTitle>
      <dateOfEvent>08/27/2025</dateOfEvent>
	  <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001817229</issuerCIK>
        <issuerCUSIP>929033108</issuerCUSIP>
		<issuerName>VOR BIOPHARMA INC.</issuerName>

        <address>
          <com:street1>100 Cambridgepark Drive, Suite 101</com:street1>
                    <com:city>Cambridge</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02140</com:zipCode>
        </address>
      </issuerInfo>

	  	  <authorizedPersons>

		<notificationInfo>
			<personName>Frank Huang, Manager</personName>
			<personPhoneNum>(415) 541-0200</personPhoneNum>
				<personAddress>
					<com:street1>101 Mission Street, Suite 1000</com:street1>
										<com:city>San Francisco</com:city>
					<com:stateOrCountry>CA</com:stateOrCountry>
					<com:zipCode>94105</com:zipCode>
				</personAddress>
		</notificationInfo>
			</authorizedPersons>
	    </coverPageHeader>

	<reportingPersons>


			<reportingPersonInfo>
									<reportingPersonCIK>0002050755</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Reprogrammed Interchange LLC</reportingPersonName>






				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>CA</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>36884567.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>36884567.00</sharedDispositivePower>
												<aggregateAmountOwned>36884567.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>29.1</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001519339</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Reid Hoffman</reportingPersonName>





				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>36884567.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>36884567.00</sharedDispositivePower>
												<aggregateAmountOwned>36884567.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>29.1</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>
			</reportingPersons>


	<items1To7>
		<item1>
			<securityTitle>Common Stock, par value $.0001 per share</securityTitle>
			<issuerName>VOR BIOPHARMA INC.</issuerName>

			<issuerPrincipalAddress>
			 <com:street1>100 Cambridgepark Drive, Suite 101</com:street1>
			  			  <com:city>Cambridge</com:city>
			  <com:stateOrCountry>MA</com:stateOrCountry>
			  <com:zipCode>02140</com:zipCode>
			</issuerPrincipalAddress>

						<commentText>This Amendment No. 1 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on Janauary 7, 2025 (the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons").

Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended.

Responses to each item of this Amendment No. 1 to Schedule 13D are incorporated by reference into the response to each other item, as applicable.</commentText>
					</item1>


				<item3>
			<fundsSource>Not applicable.</fundsSource>
		</item3>

				<item4>
			<transactionPurpose>Item 4 of Schedule 13D is hereby amended and supplemented as follows:

From August 25, 2025 through August 28, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outsanding shares of Common Stock of the Issuer.

1.  387,346 shares on August 25, 2025, at a weighted average per share sale price of $2.1163.
2.  284,190 shares on August 26, 2025, at a weighted average per share sale price of $2.0808.
3.  611,647 shares on August 27, 2025, at a weighted average per share sale price of $2.0053.
4.  806,351 shares on August 28, 2025, at a weighted average per share sale price of $2.0115.</transactionPurpose>
		</item4>

				<item5>
			 <percentageOfClassSecurities>The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 1 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5.</percentageOfClassSecurities>			<numberOfShares>Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.</numberOfShares>			<transactionDesc>Except as set forth in Item 4 above, none of the Reporting Persons has effected any transactions in the Common Stock of the Issuer during the last 60 days.</transactionDesc>			<listOfShareholders>Not applicable.</listOfShareholders>			<date5PercentOwnership>Not applicable.</date5PercentOwnership>		</item5>

				<item6>
			<contractDescription>Not applicable.</contractDescription>
		</item6>


	</items1To7>

<signatureInfo>

	<signaturePerson>
		<signatureReportingPerson>Reprogrammed Interchange LLC</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Frank Huang</signature>
				<title>Frank Huang, Manager</title>
				<date>08/29/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Reid Hoffman</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Reid Hoffman</signature>
				<title>Reid Hoffman</title>
				<date>08/29/2025</date>
			</signatureDetails>

	</signaturePerson>



</signatureInfo>
</formData>


</edgarSubmission>
